CAMBRIDGE, Mass., April 26, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and audio webcast at 8:30 a.m. ET on Wednesday, May 3, 2017 to report its first quarter 2017 financial results and provide a corporate update.

To access the live conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international), and refer to conference ID 5771361. A webcast of the call will also be available on the Investors section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2017-financial-results-on-wednesday-may-3-2017-300445904.html

SOURCE Blueprint Medicines Corporation

Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com; Media Relations: Rachel Hutman, W20 Group, 301-801-5540, rhutman@wcgworld.com